Clinical Trial Update: Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing topical 0.2% loteprednol etabonate with topical 0.1% dexamethasone in impending recurrent pterygium, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium of Eye
• Steroid-induced Glaucoma

Drugs mentioned

• Dexamethasone 0.1% topical (dexamethasone)
• Loteprednol etabonate 0.2% topical (loteprednol etabonate)

Snippet

Sponsor: Wannisa Suphachearabhan | Conditions: Recurrent Pterygium of Eye, Steroid-Induced Glaucoma | Phase 4 | Status: COMPLETED